Notably, in a recent study, the activation of MSP-RON in tumor-associated macrophages significantly increased the expression of CD80 and PD-L1, and the combination of anti-RON and anti-CTLA therapy significantly inhibited tumor growth in mice (74). The gene discussed is CD80; the disease is neoplasm.